Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin in ulcerative colitis
NCT04677179Phase 2Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 22
01
Overview
A Phase 2 trial of rezpegaldesleukin in ulcerative colitis (UC), sponsored by Nektar Therapeutics. Started Mar 2021; status: terminated.
02
Drugs
rezpegaldesleukin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04677179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677179.